Novartis Oncology Accredited as CEO Cancer Gold Standard™ Organization

Novartis Pharmaceuticals Corporation in the U.S. qualified for the CEO Cancer Gold Standard™ Accreditation, bestowed for the first time by the CEO Roundtable on Cancer.

Novartis Oncology participates in the CEO Roundtable on Cancer with 40 other companies, federal agencies and non-profits. Members play a prominent role in the national effort to eradicate cancer, working together to identify opportunities that will result in lowering the risk of cancer, enable early diagnosis, facilitate better access to the best-available treatments, and hasten the discovery of novel and more effective diagnostic tools and anti-cancer therapies.

The CEO Cancer Gold Standard is a series of cancer-related recommendations that address three goals:

• Risk Reduction
• Early Detection; and
• Quality Care.

To become accredited, organizations must demonstrate a culture that fosters healthy lifestyles and provides support when a diagnosis of cancer becomes a reality. They also need to provide programs and benefits that lower cancer risk, attempt to detect it earlier and provide access to high-quality treatment, including clinical trials.

Novartis Oncology always has been a leader in these areas. Several of the programs and policies in the Gold Standard criteria were already in place when Novartis joined the Roundtable. The Gold Standard encourages Novartis Oncology to do an even better job educating its employees about these services and educational opportunities.

Novartis Oncology is committed to keeping its employees and their families informed about advances in cancer prevention and treatment, and will continue to enhance and improve the programs and policies that earned the company the Gold Standard accreditation.